Cancer: Targeting the ubiquitin pathway
Nature Reviews Drug Discovery 17, 166 (2018).
doi:10.1038/nrd.2018.33
Author: Sarah Crunkhorn
Aberrations in the ubiquitin–proteasome system — which maintains cellular protein homeostasis — are implicated in tumour development and progression. Here, Hyer et al. report the identification of TAK-243, a first-in-class inhibitor of the ubiquitin-activating enzyme. In vitro, TAK-243 induced defective protein turnover and
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Sarah Crunkhorn Tags: Research Highlight Source Type: research